Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement